Fluent BioSciences Debuts PIPseq™ V with Unique Molecular Counting Strategy
Novel TruID™ method Increases transcript yield and overall assay sensitivity.
Designed to apply to a broad range of research needs, an assortment of PIPseq V kits address a wide scope of sample types and input levels. This scalability makes our product line an affordable option for both small and large-scale projects. The PIPseq V 3' kits bring numerous enhancements over previous versions, delivering notable improvements in both performance and workflow simplicity:
- Enhances Gene and Transcript Detection
- Streamlines Workflow
- Eliminates UMI-specific biases
- PIPseq Replay™: Re-interrogate cDNA
Our cutting-edge TruID technology leverages the random fragmentation of RNA to generate intrinsic identifiers, dramatically enhancing precision and sensitivity. This novel approach reframes the way single-cell experiments are performed and analyzed.
"As Fluent BioSciences continues to lead the charge in innovation within our field, we are delighted to offer a glimpse into an upcoming advancement in single-cell technology," said
The PIPseq V 3' Single Cell RNA Sequencing Kits are poised to set a new standard in the industry, empowering researchers with tools that enable more detailed and precise single-cell studies. Contact our team at [email protected] for more information or to purchase the PIPseq V kits.
View original content:https://www.prnewswire.com/news-releases/fluent-biosciences-debuts-pipseq-v-with-unique-molecular-counting-strategy-302158520.html
SOURCE Fluent BioSciences
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sitemetric Launches the First Agentic AI for Integrated Construction Site Access Control and Monitoring
- ARES CAPITAL CORPORATION SCHEDULES EARNINGS RELEASE FOR THE SECOND QUARTER ENDED JUNE 30, 2026
- Baidu Announces Record Date for Extraordinary General Meeting of Shareholders
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share